Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance.
In: BMC Infectious Diseases, Jg. 13 (2013-01-10), Heft 1, S. 1-22
Online
academicJournal
Zugriff:
Background Malaria remains a major public health problem in developing countries. Then in these countries prompt access to effective antimalarial treatment such as Artemisinin basedCombination Therapies (ACT) proves to be an essential tool for controlling the disease. In Senegal, since 2006 a nationwide scaling up program of ACT is being implemented. In this context it has become relevant to monitor ACT efficacy and provide recommendations for the Senegalese national malaria control program. Methods An open randomized trial was conducted during two malaria transmission seasons (2011 and 2012) to assess the efficacy and safety of three combinations: dihydro-artemisininpiperaquine (DHAPQ), artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ). The primary end point of the study was represented by a PCR adjusted adequate clinical and parasitological response (ACPR) at day 28. Secondary end points included: (i) a ACPR at days 35 and 42, (ii) a parasite and fever clearance time, (iii) ACTs safety and tolerability. The 2003 WHO's protocol for antimalarial drug evaluation was used to assess each outcome. Results Overall, 534 patients were randomized selected to receive, either ASAQ (n = 180), AL (n = 178) or DHAPQ (n = 176). The PCR adjusted ACPR at day 28 was 99.41% for the group ASAQ, while that was 100% in the AL and DHAPQ groups (p = 0.37). The therapeutic efficacy was evaluated at 99.37% in the ASAQ arm versus 100% in AL and DHAPQ arm at day 35 (p = 0.37). At day 42, the ACPR was 99.27% in the ASAQ group versus 100% for both AL and DHAPQ groups, (p = 0.36). No serious adverse event was noted during the study period. Also a similar safety profile was noted in the 3 study groups. Conclusion In the context of scaling up of ACTs in Senegal, ASAQ, AL and DHAPQ are highly effective and safe antimalarial drugs. However, it's remains important to continue to monitor their efficacy. [ABSTRACT FROM AUTHOR]
Copyright of BMC Infectious Diseases is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance.
|
---|---|
Autor/in / Beteiligte Person: | Sylla, Khadime ; Abiola, Annie ; Clément Tine, Roger ; Faye, Babacar ; Sow, Doudou ; Ndiaye, Jean Louis ; Ndiaye, Magatte ; Colé LO, Aminata ; Folly, Kuaku ; Ndiaye, Léon Amath ; Gaye, Oumar |
Link: | |
Zeitschrift: | BMC Infectious Diseases, Jg. 13 (2013-01-10), Heft 1, S. 1-22 |
Veröffentlichung: | 2013 |
Medientyp: | academicJournal |
ISSN: | 1471-2334 (print) |
DOI: | 10.1186/1471-2334-13-598 |
Schlagwort: |
|
Sonstiges: |
|